Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 78 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dengue Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus

NCT00919178
View directory record Official record
Conditions
Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Interventions
DEN4 Vaccine Candidate, DEN4 Vaccine Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01436422
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults

NCT00322946
View directory record Official record
Conditions
Dengue
Interventions
rDEN4delta30-4995, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain

NCT02372175
View directory record Official record
Conditions
Dengue
Interventions
Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults

NCT00089908
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN1delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2008 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

NCT04273217
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AV-1, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

NCT06805487
View directory record Official record
Conditions
Zika Virus
Interventions
TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

NCT02317900
View directory record Official record
Conditions
Dengue
Interventions
TV005, Placebo, rDEN2∆30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge

NCT03416036
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV-TV003 (TV003), rDEN2Δ30-7169 (DENV-2), rDEN3Δ30 (DENV-3), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age

NCT02879266
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

NCT03423173
View directory record Official record
Conditions
Dengue Fever
Interventions
TAK-003, Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
923 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Huntsville, Alabama • Anaheim, California • Boise, Idaho + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741
View directory record Official record
Conditions
DENV-3 Controlled Human Infection Model
Interventions
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults

NCT00270699
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN4delta30-200,201, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Expansion of a Dengue-1 Live Virus Human Challenge

NCT03869060
View directory record Official record
Conditions
Dengue
Interventions
Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tetravalent Chimeric Dengue Vaccine Trial

NCT01110551
View directory record Official record
Conditions
Dengue
Interventions
Placebo (SC), Placebo (ID), Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of HBV-001 D1 in Healthy Adults

NCT00936429
View directory record Official record
Conditions
Dengue Fever
Interventions
DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel), Placebo for DEN1-80E
Biological
Lead sponsor
Hawaii Biotech, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 2, 2026, 1:52 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

NCT07706686
View directory record Official record
Conditions
Healthy Volunteers, Dengue, Human Challenge Trial
Interventions
rDEN2delta30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

NCT01073306
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for Dengue Virus Subtype 2, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

NCT03999996
View directory record Official record
Conditions
Dengue Fever
Interventions
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
13 Years to 63 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
8
States / cities
Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults

NCT00118924
View directory record Official record
Conditions
Tick-Borne Encephalitis
Interventions
LGT(TP21)/DEN4, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2008 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

NCT02392325
View directory record Official record
Conditions
Dengue
Interventions
rDEN1Δ30, Placebo, rDEN2Δ30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01506570
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

NCT00290147
View directory record Official record
Conditions
Dengue
Interventions
D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

NCT03342898
View directory record Official record
Conditions
Dengue
Interventions
YF-17D, TDV, Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 2, 2026, 1:52 AM EDT